Use of specific sirna against protein s for the treatment of hemophilia
AssigneeUniversitäT Bern
InventorsRaja PRINCE EL ADNANI, Anne ANGELILLO-SCHERRER
Life of this patent
Estimating the term…
Abstract
The invention provides an siRNA against protein S for use in a method of treatment of hemophilia. Also within the scope of the present invention is a method for treating hemophilia in a patient in need thereof, comprising administering to the patient a molecule comprising a siRNA according to the invention, and a dosage form for the prevention or treatment of hemophilia, comprising a molecule comprising a siRNA according to the invention.
Claims11
An siRNA against protein S for use in a method of treatment of hemophilia.
The siRNA against protein S for use in a method of treatment of hemophilia according to any one of the above claims, wherein said siRNA is characterized by a sequence reverse complementary to SEQ ID 001 or SEQ ID 002.
The siRNA against protein S for use in a method of treatment of hemophilia according to any one of the above claims, wherein said siRNA is characterized by a sequence reverse complementary to a sequence selected from the group comprising SEQ ID NO 003, SEQ ID NO 004, SEQ ID NO 005, SEQ ID NO 006, SEQ ID NO 007, SEQ ID NO 008, SEQ ID NO 009, SEQ ID NO 010, SEQ ID NO 011, SEQ ID NO 012, SEQ ID NO 013, SEQ ID NO 014, SEQ ID NO 015, SEQ ID NO 016, SEQ ID NO 017 and SEQ ID NO 018.
The siRNA against protein S for use in a method of treatment of hemophilia according to any one of the above claims, wherein said siRNA is characterized by a sequence reverse complementary to a sequence characterized by nucleotides 1-100, 101-200, 201-300, 301-400, 301-400, 401-500, 501-600, 601-700, 701-800, 801-900, 901-1000, 1001-1100, 1101-1200, 1201-1300, 1301-1400, 1501-1600, 1701-1800, 1801-1900, 1901-2000, 2001-2100, 2101-2200, 2201-2300, 2301-2400, 2501-2600, 2701-2800, 2801-2900, 2901-3000, 3001-3100, 3101-3200, 3201-3300, 3301-3400, 3401-3500 or 3501-3580 of SEQ ID NO 001.
The siRNA against protein S for use in a method of treatment of hemophilia according to any one of the above claims, wherein said siRNA is characterized by a sequence comprising or consisting of a sequence selected from the group comprising SEQ ID NO 019 (siRNA_1), SEQ ID NO 020 (siRNA_2), SEQ ID NO 021 (siRNA_3), SEQ ID NO 022 (siRNA_4), SEQ ID NO 023 (siRNA_5), SEQ ID NO 024 (siRNA_6), SEQ ID NO 025 (siRNA_7), SEQ ID NO 026 (siRNA_8), SEQ ID NO 027 (siRNA_9), SEQ ID NO 028 (siRNA_10), SEQ ID NO 029 (siRNA_11), SEQ ID NO 030 (siRNA_12), SEQ ID NO 031 (siRNA_13), SEQ ID NO 032 (siRNA_14), SEQ ID NO 033 (siRNA_15), SEQ ID NO 034 (siRNA_16), SEQ ID NO 035 (siRNA_17), SEQ ID NO 036 (siRNA_18), SEQ ID NO 037 (siRNA_19), SEQ ID NO 038 (siRNA_20), SEQ ID NO 039 (siRNA_21), SEQ ID NO 040 (siRNA_22), SEQ ID NO 041 (siRNA_23), SEQ ID NO 042 (siRNA_24), SEQ ID NO 043 (siRNA_25), SEQ ID NO 044 (siRNA_26), SEQ ID NO 045 (siRNA_27), SEQ ID NO 046 (siRNA_28), SEQ ID NO 047 (siRNA_29), SEQ ID NO 048 (siRNA_30), SEQ ID NO 049 (siRNA_31), SEQ ID NO 050 (siRNA_32), SEQ ID NO 051 (siRNA_33), SEQ ID NO 052 (siRNA_34), SEQ ID NO 053 (siRNA_35), SEQ ID NO 054 (siRNA_36), SEQ ID NO 055 (siRNA_37), SEQ ID NO 056 (siRNA_38), SEQ ID NO 057 (siRNA_39), SEQ ID NO 058 (siRNA_40), SEQ ID NO 059 (siRNA_41), SEQ ID NO 060 (siRNA_42), SEQ ID NO 061 (siRNA_43), SEQ ID NO 062 (siRNA_44), SEQ ID NO 063 (siRNA_45), SEQ ID NO 064 (siRNA_46), SEQ ID NO 065 (siRNA_47), SEQ ID NO 066 (siRNA_48), SEQ ID NO 067 (siRNA_49), and SEQ ID NO 068 (siRNA_50).
The siRNA against protein S according to any one of the above claims for use in a method of treatment of hemophilia A.
The siRNA against protein S according to any one of the above claims for use in a method of treatment of hemophilia B.
A method for treating hemophilia in a patient in need thereof, comprising administering to the patient a molecule comprising a siRNA according to any one of the above claims.
Dependencies are inferred from the claim text.